MX2020003497A - Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos. - Google Patents
Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.Info
- Publication number
- MX2020003497A MX2020003497A MX2020003497A MX2020003497A MX2020003497A MX 2020003497 A MX2020003497 A MX 2020003497A MX 2020003497 A MX2020003497 A MX 2020003497A MX 2020003497 A MX2020003497 A MX 2020003497A MX 2020003497 A MX2020003497 A MX 2020003497A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- monospecific
- generating multispecific
- generating
- multispecific antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
Abstract
En la presente se reporta un método para la generación de anticuerpos multiespecíficos por una reacción de intercambio de mitades de anticuerpos entre dos 2/3-IgG desestabilizadas por la mitad mediante mutaciones perturbadoras asimétricas que fomentan la generación de anticuerpos biespecíficos de longitud completa correctamente ensamblados. El método se puede realizar en la ausencia de agentes reductores y no requiere enlaces de disulfuro de región bisagra en las 2/3-IgG iniciales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17197616 | 2017-10-20 | ||
PCT/EP2018/078675 WO2019077092A1 (en) | 2017-10-20 | 2018-10-19 | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003497A true MX2020003497A (es) | 2020-07-22 |
Family
ID=60268188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003497A MX2020003497A (es) | 2017-10-20 | 2018-10-19 | Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200392253A1 (es) |
EP (1) | EP3697441B1 (es) |
JP (1) | JP7450535B2 (es) |
KR (1) | KR20200067197A (es) |
CN (1) | CN111246885A (es) |
AU (1) | AU2018353420A1 (es) |
BR (1) | BR112020007154A2 (es) |
CA (1) | CA3078157A1 (es) |
IL (1) | IL273849A (es) |
MX (1) | MX2020003497A (es) |
TW (1) | TW201932142A (es) |
WO (1) | WO2019077092A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10696722B2 (en) | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
BR112021007175A2 (pt) | 2018-10-23 | 2021-08-10 | Dragonfly Therapeutics, Inc. | proteínas fundidas a fc heterodimérico |
BR112021020843A2 (pt) * | 2019-04-25 | 2022-02-01 | Hoffmann La Roche | Conjunto de polipeptídeos precursores heterodiméricos, polipeptídeos heterodiméricos, métodos para gerar um polipeptídeo heterodimérico e para identificar um polipeptídeo heterodimérico multiespecífico, polipeptídeo heterodimérico multiespecífico, primeiro e segundo polipeptídeo precursor heterodimérico |
EP3959237A1 (en) * | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
CN110669139A (zh) * | 2019-09-18 | 2020-01-10 | 沣潮医药科技(上海)有限公司 | 二聚体免疫粘附素、药物组合物和用途 |
CN111018999B (zh) * | 2019-12-05 | 2022-07-12 | 沣潮医药科技(上海)有限公司 | 二聚体免疫融合蛋白、药物组合物和用途 |
CN116601175A (zh) | 2020-12-18 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 用于靶向疗法的前体蛋白和试剂盒 |
AU2022318255A1 (en) | 2021-07-27 | 2024-01-18 | Morphosys Ag | Combinations of antigen binding molecules |
CA3235018A1 (en) * | 2021-10-15 | 2023-04-20 | Leila M. BOUSTANY | Activatable polypeptide complex |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE59610754D1 (de) | 1996-07-25 | 2003-11-06 | Gsf Forschungszentrum Umwelt | Vereinfachte herstellung bispezifischer antikörperfragmente |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
AU2003280713A1 (en) | 2003-11-04 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibody |
WO2005062916A2 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
KR101370253B1 (ko) | 2004-10-22 | 2014-03-05 | 암젠 인크 | 재조합 항체의 재접힘 방법 |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
AU2007229698B9 (en) | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
ES2654040T3 (es) | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
CL2008002886A1 (es) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
PT2235064E (pt) * | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
AU2010265933B2 (en) | 2009-06-26 | 2015-05-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
ES2617777T5 (es) | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
SI2748202T1 (sl) | 2011-08-23 | 2018-10-30 | Roche Glycart Ag | Bispecifične molekule, ki se vežejo na antigen |
CN104114579B (zh) | 2011-10-27 | 2020-01-24 | 健玛保 | 异二聚体蛋白的生成 |
CA2859667C (en) | 2011-12-20 | 2022-05-24 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
MX360109B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
BR112016006197B1 (pt) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | Método para produzir um anticorpo biespecífico de polipeptídeos |
JP6675329B2 (ja) * | 2014-06-12 | 2020-04-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn相互作用が変更された抗体を選択するための方法 |
PE20170263A1 (es) * | 2014-08-04 | 2017-03-30 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
AR102522A1 (es) * | 2014-11-06 | 2017-03-08 | Hoffmann La Roche | Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a |
EP3227332B1 (en) * | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
KR101851380B1 (ko) * | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 |
UA123323C2 (uk) | 2016-05-02 | 2021-03-17 | Ф. Хоффманн-Ля Рош Аг | Димерний злитий поліпептид |
US20190382484A1 (en) | 2017-02-24 | 2019-12-19 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition, antigen-binding molecules, treatment method, and screening method |
-
2018
- 2018-10-19 EP EP18786786.6A patent/EP3697441B1/en active Active
- 2018-10-19 JP JP2020521990A patent/JP7450535B2/ja active Active
- 2018-10-19 AU AU2018353420A patent/AU2018353420A1/en active Pending
- 2018-10-19 CN CN201880068221.9A patent/CN111246885A/zh active Pending
- 2018-10-19 BR BR112020007154-4A patent/BR112020007154A2/pt unknown
- 2018-10-19 MX MX2020003497A patent/MX2020003497A/es unknown
- 2018-10-19 CA CA3078157A patent/CA3078157A1/en active Pending
- 2018-10-19 KR KR1020207014205A patent/KR20200067197A/ko not_active Application Discontinuation
- 2018-10-19 WO PCT/EP2018/078675 patent/WO2019077092A1/en unknown
- 2018-10-19 TW TW107137080A patent/TW201932142A/zh unknown
-
2020
- 2020-04-06 IL IL273849A patent/IL273849A/en unknown
- 2020-04-15 US US16/849,223 patent/US20200392253A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200392253A1 (en) | 2020-12-17 |
EP3697441B1 (en) | 2023-06-07 |
AU2018353420A1 (en) | 2020-04-16 |
JP2021500348A (ja) | 2021-01-07 |
TW201932142A (zh) | 2019-08-16 |
WO2019077092A1 (en) | 2019-04-25 |
KR20200067197A (ko) | 2020-06-11 |
JP7450535B2 (ja) | 2024-03-15 |
CA3078157A1 (en) | 2019-04-25 |
CN111246885A (zh) | 2020-06-05 |
IL273849A (en) | 2020-05-31 |
EP3697441A1 (en) | 2020-08-26 |
BR112020007154A2 (pt) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003497A (es) | Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos. | |
MX2022000132A (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
MX2020004229A (es) | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. | |
MX2020004095A (es) | Determinacion de localizacion para operacion de vehiculo. | |
MX2018015592A (es) | Anticuerpos inhibidores de puntos de control biespecificos. | |
IL279235A (en) | DLL3-CD3 bispecific antibodies | |
MX2016012713A (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
MX2017016041A (es) | Metodos para usar activadores de piruvato cinasa. | |
MX2021003169A (es) | Metodos para purificar anticuerpos multiespecificos, heterodimericos. | |
MX2023006416A (es) | Anticuerpos, usos y metodos. | |
GB201710838D0 (en) | Bispecific antibodies | |
MX2020003754A (es) | Metodo de formacion de elementos de microimagen. | |
IL274071A (en) | A method for creating in the living body multispecific antibodies from monospecific antibodies | |
MX2020007742A (es) | Procesos para preparar fluorocetolidos. | |
IL269577B (en) | Bispecific antibodies anti–pd–l1–anti–tim–3 | |
GB201819928D0 (en) | Method for generating persulfate | |
IL282355A (en) | Bispecific antibodies directed to exosomes | |
HK1253693A1 (zh) | 產生抗t細胞受體的抗體的方法 | |
MX2020004285A (es) | Proceso para preparar el benzotiofen-2-il boronato. | |
BR112017002139A2 (pt) | ?método para preparar um composto? | |
IL276211A (en) | Process for producing hu14.18k322a monoclonal antibody | |
GB201704115D0 (en) | Method of selecting for antibodies | |
MX2018000694A (es) | Tratamiento del prurito. | |
SG11202101256TA (en) | Method for generating 3,5-dihydroxy-4-methoxybenzyl alcohol from plankton | |
EA201692246A1 (ru) | Способ получения 2,6-диметилбензохинона |